A comprehensive view of Teva Pharmaceutical Industries Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Teva recalls two lots of Matzim LA diltiazem hydrochloride hypertension drug distributed across US, Puerto Rico because extended-release tablets do not dissolve correctly; products have expirations dates of September 2022

Teva swings to Q2 GAAP net loss of US$232.0M from net profit of US$207.0M a year ago, with net revenue down at US$3.8B from US$3.9B a year ago; Capaxone sales lower than expected at US$700.0M due to increased competition, foreign exchange rates

Teva reaches tentative US$4.4B agreement to settle US opioid lawsuit; under terms of settlement Teva to provide US$1.2B of Narcan naloxone hydrochloride emergency narcotic overdose medication

Teva swings to Q2 GAAP operating loss of US$949.0M from US$582.0M income last year, with revenues down 3% from a year ago to US$3.8B; generic, OTC business benefitted from easing of COVID-19 restrictions and firm reaches agreement in opioids litigation

Teva and Allergan reach US$54M opioid lawsuit settlement with San Francisco requiring companies to pay the city US$34M in cash, provide US$20M worth of overdose reversal drug Narcan; Walgreens is only remaining defendant in lawsuit

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count